Clarity Asset Management’s Akero Therapeutics AKRO Stock Holding History

Clarity Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42	Closed	-$1.99K	–	248
2025 Q3	$1.99K	Hold	42	–	–	﹤0.01%	232
2025 Q2	$2.24K	Hold	42	–	–	﹤0.01%	230
2025 Q1	$1.7K	Hold	42	–	–	﹤0.01%	201
2024 Q4	$1.17K	Hold	42	–	–	﹤0.01%	208
2024 Q3	$1.21K	Hold	42	–	–	﹤0.01%	185
2024 Q2	$985	Hold	42	–	–	﹤0.01%	185
2024 Q1	$1.06K	Hold	42	–	–	﹤0.01%	188
2023 Q4	$981	Buy	+42	New	+$828	﹤0.01%	188

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Clarity Asset Management's AKRO Position: Q4 2025 in Review

Clarity Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 42 shares — an estimated $1.99K sold.

Clarity Asset Management first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $2.24K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Clarity Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Clarity Asset Management sold 42 Akero Therapeutics shares in Q4 2025, an estimated $1.99K.
Clarity Asset Management first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
Clarity Asset Management's Akero Therapeutics position peaked at $2.24K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Clarity Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.